|Creating the next generation of cancer treatments
May 28, 2015
Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research
Data demonstrate in-vitro activity against Ebola and other hemorrhagic fever viruses.
FLEMINGTON, NJ - May 28, 2015 - Arno Therapeutics, Inc. (OTCQB: ARNI), a clinical stage biopharmaceutical company focused on developing therapeutics in cancer and other life threatening diseases, today announced that in-vitro data for its investigational agent AR-12 (also referred to as OSU-03012) generated by the Viral Special Pathogens Branch of the U.S. Centers for Disease Control and Prevention (CDC) was published online in the journal Antiviral Research.
The AR-12 data generated by the CDC, and published by Dr. Emma L. Mohr and colleagues in the article titled Inhibitors of cellular kinases with broad-spectrum antiviral activity for hemorrhagic fever viruses," are part of a larger kinase screening program evaluating a series of compounds for potential activity against certain hemorrhagic fever viruses. The data demonstrate in-vitro activity of AR-12 against the Ebola (EBOV), Marburg, Lassa and Nipah hemorrhagic fever viruses. The concentration (ED50) of AR-12 that was found to inhibit the replication of these viruses was approximately 0.3 to 0.5 micromolar, and the cytoxic concentration (CC50) of AR-12 against the cell lines which the various viruses were grown in was approximately 5.7-8.2 micromolar with a calculated selectivity index (CC50/ED50) of 11-23 for the viral strains tested.1
Alex Zukiwski, MD, Chief Executive Officer of Arno Therapeutics, commented, "We are very encouraged by the CDC data demonstrating the in-vitro activity of AR-12 in Ebola, Marburg, Lassa and Nipah viruses. The concentrations of AR-12 which demonstrated activity against these four hemorrhagic fever viruses were approximately 10% of the plasma concentration achieved in a previous Phase 1 oncology study of AR-12. These data, along with antiviral data from other sources, provide rationale for further in-vitro and in-vivo evaluation of AR-12 against a number of viral pathogens."
Viruses rely on the underlying host cell machinery for viable viral replication. Multiple viral pathogens have evolved mechanisms to utilize (e.g. enhancement of protein folding) and subvert the host protein quality control machinery (e.g. the unfolded protein response, or UPR) to produce massive amounts of viral proteins, thereby enabling the completion of the viral life cycle.
A recent article published in the Journal of Cellular Physiology evaluated the impact of AR-12 on the expression of key host proteins involved in viral replication. The broad based antiviral activity exhibited by AR-12 is thought to be secondary to a unique mechanism of action which targets certain host cell processes that have been "hijacked" during viral replication. Investigation of AR-12 demonstrated that AR-12 suppresses expression of the GRP78 (BiP/HSPA5) chaperone, which is a key regulator of the UPR.2 Further investigation demonstrated that AR-12 also impacts other key protein chaperones including HSP70 and HSP903 both of which play important roles in viral replication. GRP78, HSP70 and HSP90 are each known to have substantial effect on viral replication. 4, 5, 6
Dr. Zukiwski added, "Targeting the host mechanisms involved in viral replication may allow for broad spectrum antiviral activity. The known safety profile of AR-12 may allow for combination therapies to be used, which together may provide a mechanism to circumvent antiviral resistance mechanisms or prevent them from developing. We look forward to further investigating the activity of AR-12 in the infectious disease setting."
About Arno Therapeutics
Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer and other life threatening disease. Arno has exclusive worldwide rights to develop and market three innovative product candidates. The lead compound, onapristone, is currently in a Phase II clinical trial in recurrent or metastatic endometrioid cancer patients with tumors expressing the activated form of the progesterone receptor. For more information about the company, please visit www.arnothera.com.
Forward-Looking Statements: This press release contains forward-looking statements that involve substantial risks and uncertainties. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include, without limitation, statements regarding the mechanism of action of AR-12, its potential to treat hemorrhagic fever viruses and other infectious diseases and Arno’s plans to further investigate AR-12 in the infectious disease setting, as well as Arno's strategy, future operations, outlook, milestones, future financial position, future financial results, plans and objectives. We may not actually achieve these plans, intentions or expectations and Arno cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make. Such factors include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of AR-12 or any of our other product candidates, our ability to finance the development of AR-12 and our other product candidates, regulatory risks, and our reliance on third party researchers and other collaborators. Additional risks are described in the company's Annual Report on Form 10-K for the year ended December 31, 2014. Arno is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
1. Mohr, E.L., et al. "Inhibitors of cellular kinases with broad-spectrum antiviral activity for hemorrhagic fever viruses." Antiviral Res. (2015), http://dx.doi.org/10.1016/j.antiviral.2015.05.003
2. Booth L. et al. "Regulation of OSU-03012 Toxicity by ER Stress Proteins and ER Stress-Inducing Drugs." Molecular Cancer Therapeutics. 2014; 13(10): 2384-2398.
3. Booth L. et al., "GRP78/ BiP/HSPA5/Dna K is a universal therapeutic target for human disease." Journal of Cellular Physiology. 2015; 9999: 1–16.
4. Reid P et al. "HSPA5 is an essential host factor for Ebola virus infection." Antiviral Research. 2014; 109: 171-174.
5. Geller R et al. "Broad action of Hsp90 as a host chaperone required for viral replication." Biochimica Biophysica Acta (BBA)-Molecular Cell Research 2012; 1823(3):698-706.
6. Mayer MP. Recruitment of Hsp70 chaperones: a crucial part of viral survival strategies. Reviews of Physiology, Biochemistry and Pharmacology. 2005: 153; 1-46.
The Ruth Group
Lee Roth (investors)
Kirsten Thomas (media)